SynthesisWorld journal of surgical oncology2026
Immune-inflammatory indices as predictors of pathologic complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review and meta-analysis of observational studies.
Synthesis in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAchieving a Pathologic complete response (pCR) after neoadjuvant chemoradiotherapy (nCRT) in patients with locally advanced rectal cancer (LARC) is associated with improved survival and organ preservation. Available blood-based inflammatory indices may help predict pCR and guide individualized treatment.
methodsThis systematic review and meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We performed a comprehensive search of PubMed, Web of Science, Scopus, and Embase, and Cochrane Library to identify studies including adult patients with pathologically confirmed LARC treated with nCRT followed by total mesorectal excision. Included studies reported categorical analyses of pre-nCRT neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), or systemic immune-inflammation (SII) in relation to pCR. Random-effects models were used to generate pooled odds ratios for high versus low index values. Heterogeneity, small-study effects, meta-regression, and the certainty of evidence using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE framework were also assessed.
resultsTwenty-four studies including 6,572 patients (20 evaluating NLR, n = 6,110; 12 PLR; n = 4,601; and 5 SII, n = 1,340) met the inclusion criteria and all were rated as high quality according to the Newcastle–Ottawa Scale. Higher pre-nCRT NLR was associated with reduced odds of pCR (pooled OR 0.60, 95% CI 0.49–0.71; I²=35.4%). High PLR similarly predicted lower pCR rates (pooled OR 0.53, 95% CI 0.37–0.69; I²=54.7%), as did higher SII (pooled OR 0.42, 95% CI 0.26–0.58; I²=27.9%). Associations were consistent across cut-off values and geographic regions. Meta. Meta-regression suggested that age, sample size, cut-off value/determination methods, tumor stage, statistical adjustment (unadjusted vs. adjusted), geographic region and other potential confounders partially explained the between-study heterogeneity.
conclusionsElevated pre-nCRT NLR and PLR were associated with lower odds of achieving pCR in patients with LARC. The evidence regarding SII was limited and should be interpreted with caution. These inexpensive and available inflammatory indices may potentially refine pre-nCRT risk stratification and identify candidates who may benefit form organ-preservation approaches.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.